Merck has reached an agreement that will let other drug makers produce its COVID-19 pill, though many countries are excluded from the pact. Merck and the United Nations-backed Medicines Patent Pool announced the agreement, saying it would help broaden access to the treatment in 105 low- and middle-income countries. The pool will be allowed to…
Merck to Let Other Drug Companies Make Its COVID-19 Pill Under New Agreement
US Set to Pay $712 Per Patient for Merck’s COVID-19 Pill
Merck is set to get $712 per treatment course for its COVID-19 pill from the U.S. government—even as it costs a fraction of that to produce, and is reportedly on track for a price of $12 in India. The gap between production costs and the price for molnupiravir is gigantic and emblematic of a problem…
Merck Shares Soar on COVID-19 Pill Trial Results, Vaccine Stocks Dip
Shares of Merck & Co surged on positive clinical trial results of its experimental antiviral COVID-19 pill while high-flying stocks of vaccine companies and makers of other coronavirus therapies were bruised. Merck shares jumped as much as 12.3 percent and hit their highest level since February 2020 after data showed the company’s pill molnupiravir could halve…
-
Recent Posts
-
Archives
- May 2025
- April 2025
- July 2023
- June 2023
- May 2023
- April 2023
- March 2023
- February 2023
- January 2023
- December 2022
- November 2022
- October 2022
- September 2022
- August 2022
- July 2022
- June 2022
- May 2022
- April 2022
- March 2022
- February 2022
- January 2022
- December 2021
- November 2021
- October 2021
- September 2021
- August 2021
- July 2021
- June 2021
- May 2021
- April 2021
- March 2021
- February 2021
- January 2021
- December 2020
- September 2013
- July 2013
- March 2013
- January 2013
- December 2012
- November 2012
- December 1
-
Meta